Regeneron's Obesity Drug Demonstrates Medically Significant Weight Loss in Phase II Clinical Trial; Phase III Study Planned for 2001 - Business Editors, Health/Medical Writers (Business Wire, 2000)
Keywords: Amyotrophic lateral sclerosis; Cardiovascular disease; Clinical trials; Diabetes; Drug dosages; Drug withdrawal; Hypertension; Hypothalamus; Obesity; Patients; Value analysis; Weight control